Phase II trial of oxaliplatin (L-OHP) in advanced, recurrent and/or metastatic squamous cell carcinoma of the head and neck.

Suppr

超能文献

作者信息

Degardin M, Cappelaere P, Krakowski I, Fargeot P, Cupissol D, Brienza S

出版信息

Eur J Cancer B Oral Oncol. 1996 Jul;32B(4):278-9. doi: 10.1016/0964-1955(95)00082-8.

DOI:10.1016/0964-1955(95)00082-8

PMID:8776427

Abstract

摘要

相似文献

Phase II trial of oxaliplatin (L-OHP) in advanced, recurrent and/or metastatic squamous cell carcinoma of the head and neck.

Eur J Cancer B Oral Oncol. 1996 Jul;32B(4):278-9. doi: 10.1016/0964-1955(95)00082-8.

Phase II trial of iproplatin in advanced squamous cell carcinoma of the head and neck, oesophagus and lung.

Eur J Cancer. 1993;29A(8):1216. doi: 10.1016/s0959-8049(05)80327-2.

Oxaliplatin, folinic acid and 5-fluorouracil (OFF) in patients with recurrent advanced head and neck cancer: a phase II feasibility study.奥沙利铂、亚叶酸钙和5-氟尿嘧啶（OFF）用于复发性晚期头颈癌患者：一项II期可行性研究。

Oral Oncol. 2006 Jul;42(6):614-8. doi: 10.1016/j.oraloncology.2005.11.001. Epub 2006 Feb 20.

Carboplatin, an active drug in advanced head and neck cancer.

Cancer Treat Rep. 1986 Oct;70(10):1173-6.

A clinical screening cooperative group phase II evaluation of lobaplatin (ASTA D-19466) in advanced head and neck cancer.洛铂（ASTA D - 19466）用于晚期头颈癌的临床筛查协作组II期评估

Invest New Drugs. 1995;13(3):253-5. doi: 10.1007/BF00873809.

Head and neck cancer: integrating anti-EGFR treatment with standard therapy.头颈癌：将抗表皮生长因子受体治疗与标准疗法相结合。

J Natl Compr Canc Netw. 2004 Sep;2 Suppl 2:S52-9.

Phase II study of iproplatin (CHIP, JM-9) in advanced squamous cell carcinoma of the head and neck.

Eur J Cancer Clin Oncol. 1987 Apr;23(4):387-9. doi: 10.1016/0277-5379(87)90374-9.

Fixed-dose every-other-week capecitabine and oxaliplatin for refractory squamous cell carcinoma of the head and neck.每两周一次固定剂量卡培他滨和奥沙利铂治疗难治性头颈部鳞状细胞癌。

Am J Med Sci. 2010 Feb;339(2):148-51. doi: 10.1097/MAJ.0b013e3181c4bd91.

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.帕博利珠单抗治疗头颈部复发或转移性鳞状细胞癌的安全性和临床活性（KEYNOTE-012）：一项开放标签、多中心、1b 期试验。

Lancet Oncol. 2016 Jul;17(7):956-965. doi: 10.1016/S1470-2045(16)30066-3. Epub 2016 May 27.

[Experimental study on the anti-tumor effects of CDDP derivatives on head and neck squamous cell carcinoma cell lines].顺铂衍生物对头颈部鳞状细胞癌细胞系抗肿瘤作用的实验研究

Gan To Kagaku Ryoho. 1988 Sep;15(9):2811-4.

引用本文的文献

Clinical Translation of Nanomedicine.纳米医学的临床转化

Chem Rev. 2015 Oct 14;115(19):11147-90. doi: 10.1021/acs.chemrev.5b00116. Epub 2015 Jun 19.

Assessment of antitumor activity and acute peripheral neuropathy of 1,2-diaminocyclohexane platinum (II)-incorporating micelles (NC-4016).含1,2 - 二氨基环己烷铂（II）的胶束（NC - 4016）的抗肿瘤活性及急性周围神经病变评估

Int J Nanomedicine. 2014 Jun 19;9:3005-12. doi: 10.2147/IJN.S60564. eCollection 2014.

Phase I pilot study of oxaliplatin, infusional 5-FU, and cetuximab in recurrent or metastatic head and neck cancer.奥沙利铂、持续输注氟尿嘧啶和西妥昔单抗治疗复发性或转移性头颈部癌症的 I 期临床试验。

Med Oncol. 2013 Mar;30(1):358. doi: 10.1007/s12032-012-0358-x. Epub 2012 Dec 25.

Phase I trial of pemetrexed plus oxaliplatin administered every other week in patients with metastatic cancer.培美曲塞联合奥沙利铂每两周给药一次用于转移性癌症患者的I期试验。

Invest New Drugs. 2008 Aug;26(4):339-45. doi: 10.1007/s10637-008-9133-4. Epub 2008 May 8.

Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies.奥沙利铂。对其在转移性结直肠癌中的药理特性、临床疗效及其在其他恶性肿瘤中的潜力的综述。

Drugs. 2000 Oct;60(4):895-924. doi: 10.2165/00003495-200060040-00005.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验